ASIVATREP

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H22F5N3O3S
Molecular Weight	491.475
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC1=NC(=CC=C1\C=C\C(=O)N[C@H](C)C2=CC(F)=C(NS(C)(=O)=O)C(F)=C2)C(F)(F)F

InChI

InChIKey=UKGJZDSUJSPAJL-YPUOHESYSA-N

InChI=1S/C21H22F5N3O3S/c1-4-5-17-13(6-8-18(28-17)21(24,25)26)7-9-19(30)27-12(2)14-10-15(22)20(16(23)11-14)29-33(3,31)32/h6-12,29H,4-5H2,1-3H3,(H,27,30)/b9-7+/t12-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C21H22F5N3O3S
Molecular Weight	491.475
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT02583009 | https://clinicaltrials.gov/ct2/show/NCT02965118 | https://clinicaltrials.gov/ct2/show/NCT02749383 | https://www.ncbi.nlm.nih.gov/pubmed/31025744 | https://adisinsight.springer.com/drugs/800048615

PAC-14028 was developed as a transient receptor potential vanilloid type 1 (TRPV1) antagonist. It is known that TRPV1 might be deeply associated with skin permeability barrier function, suggesting that modulation of TRPV1 might be beneficial for the skin disorders with barrier damages. Amorepacific developed a topical cream formulation of PAC-14028. This drug completed phase III clinical trial for the treatment of atopic dermatitis. In addition, PAC-14028 participated in phase II clinical trials to evaluate its safety and efficacy in seborrheic dermatitis and in rosacea. Moreover, PAC-14028 has been used in trials studying the treatment of pruritus.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vanilloid receptor 53 Target ID: CHEMBL4794 Sources: https://www.ncbi.nlm.nih.gov/pubmed/30623408 \| https://adisinsight.springer.com/drugs/800048615	Antagonist 2849		55.0 nM [IC50]

PubMed

Title	Date	PubMed
Novel therapeutic approach with PAC-14028 cream, a TRPV1 antagonist, for patients with mild-to-moderate atopic dermatitis.	2019-05	31025744
Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial.	2019-05	30623408
TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery.	2011-04	21345654

Patents

Sample Use Guides

In Vivo Use Guide

PAC-14028 cream 1.0% will be applied to treatment area twice daily for 8 weeks.

Route of Administration: Topical

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:46:55 GMT 2025` Edited by `admin` on `Mon Mar 31 21:46:55 GMT 2025`
Record UNII	3VF7K7Z10B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ASIVATREP

Official Name

English

Asivatrep [WHO-DD]

Preferred Name

English

(2E)-N-((1R)-1-(3,5-DIFLUORO-4-(METHANESULFONAMIDO)PHENYL)ETHYL)-3-(2-PROPYL-6-(TRIFLUOROMETHYL)PYRIDIN-3-YL)PROP-2-ENAMIDE

Systematic Name

English

asivatrep [INN]

Common Name

English

2-PROPENAMIDE, N-((1R)-1-(3,5-DIFLUORO-4-((METHYLSULFONYL)AMINO)PHENYL)ETHYL)-3-(2-PROPYL-6-(TRIFLUOROMETHYL)-3-PYRIDINYL)-, (2E)-

Systematic Name

English

PAC-14028

Common Name

English

Code System Code Type Description

SMS_ID

300000034101